Cargando…

Effects of omecamtiv mecarbil on calcium‐transients and contractility in a translational canine myocyte model

Omecamtiv mecarbil (OM) is a selective cardiac myosin activator (myotrope), currently in Phase 3 clinical investigation as a novel treatment for heart failure with reduced ejection fraction. OM increases cardiac contractility by enhancing interaction between myosin and actin in a calcium‐independent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, BaoXi, Sutherland, Weston, Vargas, Hugo M., Qu, Yusheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7512116/ https://www.ncbi.nlm.nih.gov/pubmed/32969560 http://dx.doi.org/10.1002/prp2.656

Ejemplares similares

Comprehensive in vitro pro‐arrhythmic assays demonstrate that omecamtiv mecarbil has low pro‐arrhythmic risk
por: Qu, Yusheng, et al.
Publicado: (2021)

Effects of omecamtiv mecarbil on the contractile properties of skinned porcine left atrial and ventricular muscles
por: Nakanishi, Tomohiro, et al.
Publicado: (2022)

Omecamtiv mecarbil lowers the contractile deficit in a mouse model of nebulin-based nemaline myopathy
por: Lindqvist, Johan, et al.
Publicado: (2019)

Omecamtiv mecarbil augments cardiomyocyte contractile activity both at resting and systolic Ca(2+) levels
por: Ráduly, Arnold Péter, et al.
Publicado: (2023)

Allosteric modulation of cardiac myosin dynamics by omecamtiv mecarbil
por: Hashem, Shaima, et al.
Publicado: (2017)

Effects of omecamtiv mecarbil and mavacamten in isolated human atrium
por: Abella, Lina Maria Rayo, et al.
Publicado: (2022)

Cardioprotective Properties of Omecamtiv Mecarbil against Ischemia and Reperfusion Injury
por: Stroethoff, Martin, et al.
Publicado: (2019)

Effect of Varying Degrees of Renal Impairment on the Pharmacokinetics of Omecamtiv Mecarbil
por: Trivedi, Ashit, et al.
Publicado: (2021)

Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil
por: Kaplinsky, Edgardo, et al.
Publicado: (2018)

Omecamtiv mecarbil evokes diastolic dysfunction and leads to periodic electromechanical alternans
por: Fülöp, Gábor Á., et al.
Publicado: (2021)

Effects of omecamtiv mecarbil on failing human ventricular trabeculae and interaction with (−)‐noradrenaline
por: Dashwood, Alexander, et al.
Publicado: (2021)

Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil
por: Planelles-Herrero, Vicente J., et al.
Publicado: (2017)

Orthophosphate increases the efficiency of slow muscle-myosin isoform in the presence of omecamtiv mecarbil
por: Governali, Serena, et al.
Publicado: (2020)

Omecamtiv Mecarbil: A Novel Mechanistic and Therapeutic Approach to Chronic Heart Failure Management
por: Patel, Pooja H, et al.
Publicado: (2021)

cMyBPC phosphorylation modulates the effect of omecamtiv mecarbil on myocardial force generation
por: Mamidi, Ranganath, et al.
Publicado: (2021)

Pharmacokinetic Drug‐Drug Interaction Study of Omecamtiv Mecarbil With Amiodarone and Digoxin in Healthy Subjects
por: Trivedi, Ashit, et al.
Publicado: (2021)

Safety and efficacy of omecamtiv mecarbil for heart failure: A systematic review and meta-analysis
por: Alqatati, Fadel, et al.
Publicado: (2022)

Altered Left Ventricular Rat Gene Expression Induced by the Myosin Activator Omecamtiv Mecarbil
por: El Oumeiri, Bachar, et al.
Publicado: (2023)

Effects of the cardiac myosin activator Omecamtiv-mecarbil on severe chronic aortic regurgitation in Wistar rats
por: El-Oumeiri, Bachar, et al.
Publicado: (2018)

Positive cardiac inotrope omecamtiv mecarbil activates muscle despite suppressing the myosin working stroke
por: Woody, Michael S., et al.
Publicado: (2018)

The myosin activator omecamtiv mecarbil improves wall stress in a rat model of chronic aortic regurgitation
por: El Oumeiri, Bachar, et al.
Publicado: (2021)

Omecamtiv mecarbil treatment improves post-resuscitation cardiac function and neurological outcome in a rat model
por: Wu, Shih-Ni, et al.
Publicado: (2022)

Generative adversarial networks for construction of virtual populations of mechanistic models: simulations to study Omecamtiv Mecarbil action
por: Parikh, Jaimit, et al.
Publicado: (2021)

Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial
por: Metra, Marco, et al.
Publicado: (2022)

Characterization of Stimulatory Action on Voltage-Gated Na(+) Currents Caused by Omecamtiv Mecarbil, Known to Be a Myosin Activator
por: Ting, Chih-Yu, et al.
Publicado: (2023)

Oxytocin does not directly alter cardiac repolarization in rabbit or human cardiac myocytes
por: Qu, Yusheng, et al.
Publicado: (2015)

Opposite diastolic effects of omecamtiv mecarbil versus dobutamine and ivabradine co‐treatment in pigs with acute ischemic heart failure
por: Rønning, Leif, et al.
Publicado: (2018)

Myosin with hypertrophic cardiac mutation R712L has a decreased working stroke which is rescued by omecamtiv mecarbil
por: Snoberger, Aaron, et al.
Publicado: (2021)

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC‐HF baseline characteristics and comparison with contemporary clinical trials
por: Teerlink, John R., et al.
Publicado: (2020)

Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure: Results From the COSMIC-HF Study
por: Felker, G. Michael, et al.
Publicado: (2020)

Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects
por: Palaparthy, Rameshraja, et al.
Publicado: (2016)

Omecamtiv mercabil and blebbistatin modulate cardiac contractility by perturbing the regulatory state of the myosin filament
por: Kampourakis, Thomas, et al.
Publicado: (2017)

Calcium Signaling and Contractility in Cardiac Myocyte of Wolframin Deficient Rats
por: Cagalinec, Michal, et al.
Publicado: (2019)

Evaluation of drug‐drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically‐based pharmacokinetic model
por: Trivedi, Ashit, et al.
Publicado: (2021)

Influence of the tubular network on the characteristics of calcium transients in cardiac myocytes
por: Marchena, Miquel, et al.
Publicado: (2020)

Reversible and Irreversible Effects of Electroporation on Contractility and Calcium Homeostasis in Isolated Cardiac Ventricular Myocytes
por: Chaigne, Sébastien, et al.
Publicado: (2022)

Direct, Differential Effects of Tamoxifen, 4-Hydroxytamoxifen, and Raloxifene on Cardiac Myocyte Contractility and Calcium Handling
por: Asp, Michelle L., et al.
Publicado: (2013)

KChIP2 regulates the cardiac Ca(2+) transient and myocyte contractility by targeting ryanodine receptor activity
por: Nassal, Drew M., et al.
Publicado: (2017)

Linking metabolic and contractile dysfunction in aged cardiac myocytes
por: Barton, Gregory P., et al.
Publicado: (2017)

Cardiac myocyte intrinsic contractility and calcium handling deficits underlie heart organ dysfunction in murine cancer cachexia
por: Law, Michelle L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bjjjif181v6q66e1l59r233f8d